Best of Dermatology Coverage in 2022

The agency assigned prademagene zamikeracel a PDUFA target action date of April 29, 2025.

“Emrosi has potential to become the best-in-class oral medication to treat the condition,” said the CEO of Journey Medical.

The monoclonal antibody was also approved for active non-radiographic axial spondyloarthritis and active ankylosing spondylitis.

LEO Pharma expects the regulatory review process to be completed in the second half of 2025.

Lebrikizumab-lbks is a targeted treatment that addresses the root cause of atopic dermatitis; by reducing inflammation throughout the body, it can help alleviate the dry, itchy, and irritated skin that often characterizes the condition.

LEO Pharma presented data from 2 of the largest multinational real-world studies on the prevalence, severity and treatment of chronic hand eczema at the European Society of Contact Dermatitis congress.